Aiming at using the lytic power of the cellular immune response, Rosenberg and his team at the NCI (Surgical Branch, NIH, Bethesda, MD) established technologies in the early 1980s to generate ex vivo cytotoxic cells in the presence of interleukin (IL)-2, so-called lymphokine-activated killer (LAK) cells, an enriched cell product with lytic activities.9 LAK cells attracted interest due to their ability to kill cancer cells in vitro that are resistant to NK cell-mediated lysis. Here, IL2 is linked to cancer.